The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, positioning the oral, brain-penetrant molecular glue degrader as a potential option after multiple ALK TKI lines. TRI-611 is designed to eliminate ALK fusion proteins through targeted protein degradation using cereblon-mediated ubiquitination, rather than classic ALK kinase active-site inhibition. Fast Track does not equal approval, but it enables more frequent FDA interactions and can support accelerated development programs for serious conditions with unmet medical needs. For biotech development teams, the designation highlights continued regulatory interest in degradation modalities in precision oncology—especially where CNS penetration and resistance after serial TKIs remain key barriers.